As of September 30, 2026, Bioventus Inc. carries a market capitalization of 933.04M, placing it among publicly traded companies globally. Its enterprise value stands at 1.18B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 933.04M |
| Enterprise Value | 1.18B |
Bioventus Inc.'s next confirmed earnings release is scheduled for March 11, 2027.
| Earnings Date | 3/11/2027 |
As of September 30, 2026, Bioventus Inc. has 68.45M shares outstanding.
| Shares Outstanding | 68.45M |
As of September 30, 2026, Bioventus Inc. trades at a trailing price-to-earnings ratio of 16.09. The price-to-sales ratio is 1.57, and the price-to-book ratio stands at 3.88.
| PE Ratio | 16.09 |
| PS Ratio | 1.57 |
| PB Ratio | 3.88 |
| P/TBV Ratio | -8.41 |
| P/FCF Ratio | 11.33 |
| P/OCF Ratio | 10.54 |
As of September 30, 2026, Bioventus Inc. trades at an EV/EBITDA multiple of 11.73 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.02 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. Its EV/EBIT multiple of 20.86 values the business against core operating earnings after depreciation, a stricter test than EV/EBITDA for capital-intensive businesses. These enterprise value multiples are built on an enterprise value of 1.18B versus a market cap of 933.04M, with the gap driven by net debt and cash on the balance sheet.
| EV / Sales | 2.02 |
| EV / EBITDA | 11.73 |
| EV / EBIT | 20.86 |
As of September 30, 2026, Bioventus Inc. maintains a current ratio of 1.68, meaning it holds 1.7x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 78.74, indicating elevated leverage, while an interest coverage ratio of 5.78 demonstrates adequate ability to service its debt obligations.
| Current Ratio | 1.68 |
| Quick Ratio | 1.07 |
| Debt / Equity | 78.74 |
| Debt / EBITDA | 2.28 |
| Interest Coverage | 5.78 |
Over the twelve months ended September 30, 2026, Bioventus Inc. posted a return on equity (ROE) of 28.18, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 8.33, measuring how efficiently the asset base is converted into earnings. The company generates approximately 629,719.35 in revenue per employee across its workforce of 930.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.04 indicates how many times Bioventus Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.
| Return on Equity (ROE) | 28.18 |
| Return on Assets (ROA) | 8.33 |
| Revenue Per Employee | 629,719.35 |
| Employee Count | 930.00 |
| Inventory Turnover | 2.04 |
Over the twelve months ended September 30, 2026, Bioventus Inc. recorded an income tax benefit of -24.20M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. Taxes are levied on pretax income of 40.13M, leaving 57.30M in net income after tax - the gap is what shifts in the tax rate do to reported earnings and EPS.
| Income Tax | -24.20M |
As of the close on November 16, 2026, Bioventus Inc.'s stock has gained approximately 42.31% over the past 52 weeks. The 50-day moving average sits at 13.06, while the 200-day moving average is 11.08.
| 52-Week Price Change | 42.31% |
| 50-Day Moving Average | 13.06 |
| 200-Day Moving Average | 11.08 |
Over the twelve months ended September 30, 2026, Bioventus Inc. generated 585.64M in revenue and converted that into 57.30M in net income, yielding earnings per share of 0.91. EBITDA reached 100.89M, while operating income came in at 59.00M.
| Revenue | 585.64M |
| Gross Profit | 402.35M |
| Operating Income | 59.00M |
| Pretax Income | 40.13M |
| Net Income | 57.30M |
| EBITDA | 100.89M |
| EBIT | 56.73M |
| Earnings Per Share (EPS) | 0.91 |
As of September 30, 2026, Bioventus Inc. holds 30.71M in cash and equivalents against 229.83M in total debt, resulting in a net debt position of 199.12M. Total book value stands at 240.50M, with working capital of 107.84M providing operational flexibility.
| Cash & Cash Equivalents | 30.71M |
| Total Debt | 229.83M |
| Net Debt | 199.12M |
| Equity (Book Value) | 240.50M |
| Book Value Per Share | 3.51 |
| Working Capital | 107.84M |
Bioventus Inc. produced 87.43M in operating cash flow over the twelve months ended September 30, 2026. After subtracting -2.45M in capital expenditures, free cash flow totaled 84.99M - equivalent to 1.26 per share.
| Operating Cash Flow | 87.43M |
| Capital Expenditures | -2.45M |
| Free Cash Flow | 84.99M |
| FCF Per Share | 1.26 |
Over the twelve months ended September 30, 2026, Bioventus Inc. posted a gross margin of 68.70, reflecting its pricing power and cost economics. The operating margin of 10.07 and net profit margin of 9.78 provide insight into operational efficiency.
| Gross Margin | 68.70 |
| Operating Margin | 10.07 |
| Pretax Margin | 6.85 |
| Profit Margin | 9.78 |
| EBITDA Margin | 17.23 |
These figures cover the twelve months ended September 30, 2026. Free cash flow yield stands at 8.83, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 9.93, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Bioventus Inc. shareholders.
| Shareholder Yield | 9.93 |
| FCF Yield | 8.83 |
As of September 30, 2026, Bioventus Inc. has an Altman Z-Score of 3.02, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 3.02 |